Event Date: Wednesday, September 29, 2021
Time: 1:00 p.m. ET
Zoom Webinar (Free — Registration Required)
This lecture will describe the US FDA approval of aducanumab (Aduhelm) for Alzheimer disease and the implications the approval has had across the US health care system. Specifically, the role that independent health technology assessment (HTA) played following the decision and the implications of the “new” standards for FDA approval will be explored. The lecture will also look forward ― what options do policy-makers and clinicians have to leverage HTA in support of better outcomes for patients and the health care system?
With more than 20 years of experience in the business and policy of health care, Sarah leads strategic operations for leading non-profit health policy research organization, ICER ― the Institute for Clinical and Economic Review ― as its Executive Vice-President and Chief Operating Officer.
Prior to joining ICER, Sarah spent 6 years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a health care communications firm. Sarah began her career in clinical research at Beth Israel Deaconess Medical Center in Boston.
Sarah holds a Master of Public Policy degree, with a concentration in health policy, from the Heller School at Brandeis University and received a bachelor’s degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based health care.